Drug Trial Radar · NCT05395533
A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL.
Last checked: Nov 19, 2026Latest source record: Jun 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
147
Actual
Start
Sep 8, 2020
Primary completion
Jul 31, 2025
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- Zhejiang Teruisi Pharmaceutical Inc.Industry
- Sponsor type
- Industry
- First posted
- May 27, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is a multicenter, open, single arm, dose increasing and extended clinical trial. The dose was increased according to the "3 + 3" rule. Patients with recurrent or refractory CD20 positive B-cell non-Hodgkin's lymphoma were selected to evaluate the safety, tolerance (DLT, MTD) and pharmacokinetic (PK) characteristics of TRS005 by intravenous drip.
Conditions
- CD20-positive B-cell Non-Hodgkin Lymphoma
Interventions
Recombinant CD20 monoclonal antibody-MMAE conjugte for injectionDrug
The dose of the enrolled subjects was increased according to the following 6 dose groups: 0.1mg/kg, 0.5mg/kg, 1.0mg/kg, 1.5mg/kg, 1.8mg/kg, and 2.1mg/kg.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Dose-limiting ToxicityTime frame: Cycle 1(Days 1-21)
- MTD,Maximum Tolerated DoseTime frame: Cycle 1(Days 1-21)
- Number of Participants With Treatment-emergent Adverse Event (TEAE)Time frame: Baseline up to approximately 5 years
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Chinese Academy of Medical Sciences, Cancer Hospital
Beijing, Beijing Municipality, China
Sun Yat-sen University Cancer Center (SYSUCC)
Guangzhou, Guangdong, China
Henan Cancer Hospital (Affiliated Cancer Hospital of Zhengzhou University)
Zhengzhou, Henan, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Second Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Tianjin Medical University Cancer Institute & Hospital (TMUCIH)
Tianjin, Tianjin Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.